The arrival of Retatrutide ZPHC, at a dosage of 120mg, is creating considerable buzz within the healthcare community. This groundbreaking dual GIP and GLP-1 agonist medication suggests to provide significant improvements in fat shedding compared to current therapies. Initial patient data have demonstrated significant decreases in weight , potential